多家药物制造商因杂质和标签错误而召回了200 000多个单位。 Multiple drug manufacturers recall over 200,000 units due to impurities and labeling errors.

药品制造商Aurobindo Pharma、Glenmark和Zydus因制造问题在美国市场召回了几种产品,据林业发展局报告。 Drug manufacturers Aurobindo Pharma, Glenmark, and Zydus have recalled several products in the US market due to manufacturing issues, as reported by the FDA. Aurobindo Pharma United States因杂质而回收了10万瓶Cinacalcecket药片。 Aurobindo Pharma USA recalled over 100,000 bottles of Cinacalcet tablets due to an impurity. Glenmark制药公司出于同样的原因召回了大约90,000瓶Diltiazem氢氯化物胶囊。 Glenmark Pharmaceuticals recalled around 90,000 bottles of Diltiazem Hydrochloride capsules for the same reason. 由于标签错误,Zydus制药公司召回了4,404包Ecomeprazole镁。 Zydus Pharmaceuticals recalled 4,404 packs of Esomeprazole Magnesium due to a labeling error. 所有召回都归类为第二类,表明可能出现暂时或可逆转的健康问题。 All recalls are classified as Class II, indicating potential for temporary or reversible health issues.